Effects of glutamate antagonists on nigral dopamine release in the reserpine-treated rat.
Biggs
C
C
Department of Pharmacology, School of Pharmacology, London, U.K.
Starr
M
M
Fowler
L
L
Whitton
P
P
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology; D000818:Animals; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D018698:Glutamic Acid / Q000378:metabolism*; D007980:Levodopa / Q000494:pharmacology; D008781:Methyltyrosines / Q000494:pharmacology; D020891:Raclopride; D051381:Rats; D012110:Reserpine / Q000494:pharmacology*; D012457:Salicylamides / Q000494:pharmacology; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism*; D019805:alpha-Methyltyrosine
D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D018691:Excitatory Amino Acid Antagonists; D008781:Methyltyrosines; D012457:Salicylamides; D018698:Glutamic Acid; D020891:Raclopride; D007980:Levodopa; D019805:alpha-Methyltyrosine; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D016291:Dizocilpine Maleate; D012110:Reserpine; D004298:Dopamine